Phase 2 trial of nonpegylated doxorubicin (Myocet) as second-line treatment in advanced or recurrent endometrial cancer
Articolo
Data di Pubblicazione:
2011
Citazione:
Di Legge, A., Trivellizzi, I., Moruzzi, M., Pesce, A., Scambia, G., Lorusso, D., Phase 2 trial of nonpegylated doxorubicin (Myocet) as second-line treatment in advanced or recurrent endometrial cancer, <>, 2011; 21 (8): 1446-1451. [doi:10.1097/IGC.0b013e31822d754e] [http://hdl.handle.net/10807/3748]
Abstract:
Advanced or recurrent endometrial cancer is associated with a poor prognosis, and results obtained with systemic therapy are far from being impressive. Myocet is an interesting formulation of citrate conjugated doxorubicin encapsulated in nonpegylated liposomes. This phase 2 study was designed to evaluate the objective response rate and the toxicity profile of Myocet in women with advanced or recurrent endometrial cancer.
Tipologia CRIS:
Articolo in rivista, Nota a sentenza
Keywords:
Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma; Doxorubicin; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Treatment Failure
Elenco autori:
Di Legge, Alessia; Trivellizzi, In; Moruzzi, Mc; Pesce, Alessandra; Scambia, Giovanni; Lorusso, Domenica
Link alla scheda completa:
Pubblicato in: